FMFederico Monczor

Federico Monczor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Federico Monczor has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Carina Shayo

    Laboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental CONICET Buenos Aires Argentina

    9 shared publications
  • Carlos Davio

    Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA) Universidad de Buenos Aires Buenos Aires Argentina

    7 shared publications
  • Natalia Fernandez

    Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, 1113, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, 1113, Argentina

    7 shared publications
  • Carlos Daniel Zappia

    Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA) Universidad de Buenos Aires Buenos Aires Argentina

    4 shared publications
  • Carlos P. Fitzsimons

    University of Amsterdam

    3 shared publications
  • Gina Granja-Galeano

    Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, 1113, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, 1113, Argentina

    3 shared publications

Latest Publications

  • Open Access

    Cross‐Talk Between Histamine H 2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment

    by Valeria Torralba‐Agu, Natalia Fernández, Carina Shayo, Carlos Davio, C. Daniel Zappia, Federico Monczor

    This study investigates the impact of histamine H 2 receptor activation on glucocorticoid receptor (GR)‐mediated transcriptional activity, as well as its effects on leukemic cell proliferation and chemotherapy resistance. We demonstrate that activation of the histamine H 2 receptor by its specific agonist, amthamine, enhances GR transcriptional activity induced by dexamethasone in both artificial promoter‐driven luciferase reporter assays and endogenous GR‐responsive genes. Mechanistically, histamine H 2 receptor signaling exerts a dual regulatory effect: an inhibitory influence mediated by cAMP and a stimulatory effect through inhibition of the PI3K‐AKT–mTOR‐S6K pathway and activation of the ERK pathway. Furthermore, while dexamethasone reduces leukemic cell proliferation at high doses, it increases it at lower concentrations, an effect that is abrogated by amthamine. Moreover, the combination of the glucocorticoid and the H 2 agonist reestablishes leukemic cell sensitivity to cytarabine, thereby restoring its cytotoxicity. Together, these findings offer insight into the molecular mechanisms and therapeutic potential of the interplay between histamine H 2 ligands and GR agonists, and may help guide dosage optimization and mitigate the well‐known side effects of glucocorticoid therapy, with potential clinical implications for the treatment of acute myeloid leukemia.

  • CB1 receptor expression and signaling are required for dexamethasone-induced aversive memory consolidation

    by Gina Granja-Galeano, Ana Paula Dominguez-Rubio, C. Daniel Zappia, Manuel Wolfson, Sara Sanz-Blasco, Julieta Aisemberg, Maria Zorrilla-Zubilete, Natalia Fernandez, Ana Franchi, Carlos P. Fitzsimons, et al.


  • Open Access

    Novel inhibitors of phosphorylation independent activity of GRK2 modulate cAMP signaling

    by Emiliana Echeverría, Sonia Ripoll, Lucas Fabián, Carina Shayo, Federico Monczor, Natalia C. Fernández

    G protein‐coupled receptors kinase 2 (GRK2) plays a major role in receptor regulation and, as a consequence, in cell biology and physiology. GRK2‐mediated receptor desensitization is performed by its kinase domain, which exerts receptor phosphorylation promoting G protein uncoupling and the cessation of signaling, and by its RGS homology (RH) domain, able to interrupt G protein signaling. Since GRK2 activity is exacerbated in several pathologies, many efforts to develop inhibitors have been conducted. Most of them were directed toward GRK2 kinase activity and showed encouraging results on in vitro systems and animal models. Nevertheless, limitations including unspecific effects or pharmacokinetics issues prevented them from advancing to clinical trials. Surprisingly, even though the RH domain demonstrated the ability to desensitize GPCRs, this domain has been less explored. Herein, we show in vitro activity of a series of compounds that, by inhibiting GRK2 RH domain, increase receptor cAMP response, avoid GRK2 translocation to the plasma membrane, inhibit coimmunoprecipitation of GRK2 with Gαs subunit of heterotrimeric G protein, and prevent receptor desensitization. Also, we preliminarily evaluated candidates’ ADMET properties and observed suitable lipophilicity and cytotoxicity. These novel inhibitors of phosphorylation‐independent actions of GRK2 might be useful in elucidating other RH domain roles and lay the foundation for the development of innovative pharmacologic therapy for diseases where GRK2 activity is exacerbated.


  • Open Access

    Antihistamines Potentiate Dexamethasone Anti-Inflammatory Effects. Impact on Glucocorticoid Receptor-Mediated Expression of Inflammation-Related Genes

    by Carlos Daniel Zappia, Valeria Torralba-Agu, Emiliana Echeverria, Carlos P. Fitzsimons, Natalia Fernández, Federico Monczor

    Antihistamines and glucocorticoids (GCs) are often used together in the clinic to treat several inflammation-related situations. Although there is no rationale for this association, clinical practice has assumed that, due to their concomitant anti-inflammatory effects, there should be an intrinsic benefit to their co-administration. In this work, we evaluated the effects of the co-treatment of several antihistamines on dexamethasone-induced glucocorticoid receptor transcriptional activity on the expression of various inflammation-related genes in A549 and U937 cell lines. Our results show that all antihistamines potentiate GCs’ anti-inflammatory effects, presenting ligand-, cell- and gene-dependent effects. Given that treatment with GCs has strong adverse effects, particularly on bone metabolism, we also examined the impact of antihistamine co-treatment on the expression of bone metabolism markers. Using MC3T3-E1 pre-osteoblastic cells, we observed that, though the antihistamine azelastine reduces the expression of dexamethasone-induced bone loss molecular markers, it potentiates osteoblast apoptosis. Our results suggest that the synergistic effect could contribute to reducing GC clinical doses, ineffective by itself but effective in combination with an antihistamine. This could result in a therapeutic advantage, as the addition of an antihistamine may reinforce the wanted effects of GCs, while related adverse effects could be diminished or at least mitigated. By modulating the patterns of gene activation/repression mediated by GR, antihistamines could enhance only the desired effects of GCs, allowing their effective dose to be reduced. Further research is needed to correctly determine the clinical scope, benefits, and potential risks of this therapeutic strategy.


  • Open Access

    South American special issue: Editorial

    by Federico Monczor, Ana Genaro

  • Biased agonism at histamine H1 receptor: Desensitization, internalization and MAPK activation triggered by antihistamines

    by Valeria Burghi, Emiliana B. Echeverría, Carlos D. Zappia, Antonela Díaz Nebreda, Sonia Ripoll, Natalia Gómez, Carina Shayo, Carlos A. Davio, Federico Monczor, Natalia C. Fernández


  • Histamine Receptors

    by Natalia C. Fernández, Federico Monczor

  • Histamine Receptors

    by Natalia C. Fernández, Federico Monczor

  • Open Access

    Therapeutic utility of glucocorticoids and antihistamines cotreatment. Rationale and perspectives

    by Carlos D. Zappia, Federico Monczor

    Antihistamines and glucocorticoids (GCs) are often used together in the clinic, in several inflammatory‐related situations. Even though there is no clear rationale for this drug association, the clinical practice is based on the assumption that due to their concomitant antiinflammatory effects, there should be an intrinsic benefit in their coadministration. Our group has studied the molecular interaction between the histamine H1 receptor and the glucocorticoid receptor (GR) signaling pathways, showing an enhancing effect on GC‐induced GR transcriptional activity induced by antihistamines. We hypothesize that the existence of this synergistic effect could contribute in reducing the GCs clinical doses, ineffective by itself but effective in combination with an antihistamine. This could result in a therapeutic advantage as the GC‐desired effects may be reinforced by the addition of an antihistamine and, as a consequence of the dose reduction, GC‐related adverse effects could be reduced or at least mitigated. Here we discuss the potential therapeutic applications of this cotreatment seeking to evaluate its usefulness, especially in inflammatory‐related conditions.


  • Open Access

    Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model

    by Carlos D. Zappia, Ariadna Soto, Gina Granja‐Galeano, Ignacio Fenoy, Natalia Fernandez, Carlos A. Davio, Carina Shayo, Carlos P. Fitzsimons, Alejandra Goldman, Federico Monczor

    Glucocorticoids are among the most effective drugs to treat asthma. However, the severe adverse effects associated generate the need for its therapeutic optimization. Conversely, though histamine is undoubtedly related to asthma development, there is a lack of efficacy of antihistamines in controlling its symptoms, which prevents their clinical application. We have reported that antihistamines potentiate glucocorticoids’ responses in vitro and recent observations have indicated that the coadministration of an antihistamine and a synthetic glucocorticoid has synergistic effects on a murine model of allergic rhinitis. Here, the aim of this work is to establish if this therapeutic combination could be beneficial in a murine model of asthma. We used an allergen‐induced model of asthma (employing ovalbumin) to evaluate the effects of the synthetic glucocorticoid dexamethasone combined with the antihistamine azelastine. Our results indicate that the cotreatment with azelastine and a suboptimal dose of dexamethasone can improve allergic lung inflammation as shown by a decrease in eosinophils in bronchoalveolar lavage, fewer peribronchial and perivascular infiltrates, and mucin‐producing cells. In addition, serum levels of allergen‐specific IgE and IgG1 were also reduced, as well as the expression of lung inflammatory‐related genes IL‐4, IL‐5, Muc5AC, and Arginase I. The potentiation of dexamethasone effects by azelastine could allow to reduce the effective glucocorticoid dose needed to achieve a therapeutic effect. These findings provide first new insights into the potential benefits of glucocorticoids and antihistamines combination for the treatment of asthma and grants further research to evaluate this approach in other related inflammatory conditions.